2016


To access this material please log in or register

Register Authorize
2016/№4

Left ventricular hypertrophy in arterial hypertension as an indicator of cardiovascular risk and the the goal for antihypertensive therapy

Nechaeva G. I., Semenkin A. A., Chindareva O. I., Makhrova N. V.
State Budgetary Educational Institution of Higher Professional Education, “Omsk State Medical University” of the RF Ministry of Health Care, Lenina 12, Omsk 644043

Keywords: arterial hypertension, left ventricle hypertrophy, pathogenesis, prognosis, diagnostic methods, antihypertensive therapy

DOI: 10.18087 / rhj.2016.4.2218

The article reviews pathogenetic aspects and prognostic significance of left ventricular hypertrophy in arterial hypertension, gives comparative characteristics of current diagnostic methods, discusses the problems of medical therapies aimed to its correction.
  1. Оганов Р. Ф., Константинов В. В., Тимофеева Т. Н., Колтунов И. Е., Баланова Ю. А., Капустина А. В. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваскулярная терапия и профилактика. 2011;10 (1):9–13 [Oganov R. F., Konstantinov V. V., Timofeeva T. N., Koltunov I. E., Balanova Yu. A., Kapustina A. V. i dr. E`pidemiologiya arterial`noj gipertonii v Rossii. Rezul`taty` federal`nogo monitoringa 2003–2010 gg. Kardiovaskulyarnaya terapiya i profilaktika. 2011;10 (1):9–13].
  2. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH / ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31 (7):1281–357.
  3. Pieruzzi F, Antolini L, Salerno F, Giussani M, Brambilla P, Galbiati S et al. The role of blood pressure, body weight and fat distribution on left ventricular mass, diastolic function and cardiac geometry in children. J Hypertens. 2015 Jun;33 (6):1182–92.
  4. Fagard R, Staessen J, Thijs S, Amery A. Multiple standardized clinic blood pressures may predict left ventricular mass as well as ambulatory monitoring. A metaanalysis of comparative studies. Am J Hypertens. 1995 May;8 (5 Pt 1):533–40.
  5. Julien J, Tranche C, Souchet T. Left ventricular hypertrophy in hypertensive patients. Epidemiology and prognosis. Arch Mal Coeur Vaiss. 2004 Mar;97 (3):221–7.
  6. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10–16;366 (9489):895–906.
  7. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4;359 (23):2417–28.
  8. Драпкина О. М., Кабурова А. Н. Жесткость сосудов и диастолическая сердечная недостаточность. Терапевтический архив. 2013;85 (11):75–81 [Drapkina O. M., Kaburova A. N. Zhestkost` sosu­dov i diastolicheskaya serdechnaya nedostatochnost`. Terapev­ticheskij arxiv. 2013;85 (11):75–81].
  9. Berkin KE, Ball SG. Essential hypertension: the heart and hypertension. Heart. 2001 Oct;86 (4):467–75.
  10. Wassmann S, Nickenig G. Pathophysiological regulation of the AT1‑re­ceptor and implications for vascular disease. J Hypertens Suppl. 2006 Mar;24 (1):15–21.
  11. Malik FS, Lavie CJ, Mehra MR, Milani RV, Re RN. Renin-angiotensin system: genes to bedside. Am Heart J. 1997 Sep;134 (3):514–26.
  12. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med. 1996 Jun 20;334 (25):1649–54.
  13. Pellieux C, Sauthier T, Aubert JF, Brunner HR, Pedrazzini T. Angiotensin II-induced cardiac hypertrophy is associated with different mitogen-activated protein kinase activation in normotensive and hypertensive mice. J Hypertens. 2000 Sep;18 (9):1307–17.
  14. Weber KT, Brilla CG, Campbell SE, Guarda E, Zhou G, Sriram K. Myocardial fibrosis: role of angiotensin II and aldosterone. Basic Res Cardiol. 1993;88 (Suppl 1):107–24.
  15. Laks MM, Morady F. Norepinephrine – the myocardial hypertrophy hormone? Am Heart J. 1976 May;91 (5):674–5.
  16. Rapacciuolo A, Esposito G, Caron K, Mao L, Thomas SA, Rockman HA. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol. 2001 Sep;38 (3):876–82.
  17. Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000 Jun;13 (6 Pt 2):99S-105S.
  18. Adiarto S, Heiden S, Vignon-Zellweger N, Nakayama K, Yanagisawa M, Emoto N. ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci. 2012 Oct 15;91 (13-14):651–7.
  19. Díez J, Laviades C. Insulin-like growth factor-1 and cardiac mass in essential hypertension: comparative effects of captopril, lisinopril and quinapril. J Hypertens Suppl. 1994 Jul;12 (4):S31–6.
  20. Zhan CD, Wang TH, Pan J. The role of nitric oxide in the angiotensin II-induced hypertrophy of cardiac myocytes. Sheng Li Xue Bao. 1999 Dec;51 (6):660–6.
  21. Cuspidi C, Rescaldani M, Sala C, Grassi G. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. J Hypertens. 2014 Jan;32 (1):16–25.
  22. Дедов И. И., Александров А. А., Кухаренко С. С. Сердце и ожирение. Ожирение и метаболизм. 2006;1:14–20 [Dedov I. I., Aleksandrov A. A., Kuxarenko S. S. Serdcze i ozhirenie. Ozhirenie i metabolizm. 2006;1:14–20].
  23. De Simone G, Palmieri V, Bella JN, Celentano A, Hong Y, Oberman A et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens. 2002 Feb;20 (2):323–31.
  24. De Kreutzenberg SV, Avogaro A, Tiengo A, Del Prato S. Left ventricular mass in type 2 diabetes mellitus. A study employing a simple ECG index: the Cornell voltage. J Endocrinol Invest. 2000 Mar;23 (3):139–44.
  25. Paolisso G, Tagliamonte MR, Galderisi M, Zito GA, D’Errico A, Marfella R et al. Plasma leptin concentration, insulin sensitivity, and 24‑hour ambulatory blood pressure and left ventricular geometry. Am J Hypertens. 2001 Feb;14 (2):114–20.
  26. Lewis JF, Maron BJ. Cardiovascular consequences of the aging process. Cardiovasc Clin. 1992;22 (2):25–34.
  27. Badano L, Carratino L, Giunta L, Calisi P, Lucatti A. Age-induced changes in the cardiovascular system in normal subjects. G Ital Cardiol. 1992 Sep;22 (9):1023–34.
  28. Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med. 1988 Jan;108 (1):7–13.
  29. Pearson AC, Gudipati CV, Labovitz AJ. Effects of aging on left ventricular structure and function. Am Heart J. 1991 Mar;121 (3 Pt 1):871–5.
  30. Daniels SD, Meyer RA, Loggie JM. Determinants of cardiac involvement in children and adolescents with essential hypertension. Circulation. 1990 Oct;82 (4):1243–8.
  31. Antikainen R, Grodzicki T, Palmer AJ, Beevers DG, Coles EC, Webster J, Bulpitt CJ. The determinants of left ventricular hypertrophy defined by Sokolow-Lyon criteria in untreated hypertensive patients. J Hum Hypertens. 2003 Mar;17 (3):159–64.
  32. Marcus R, Krause L, Weder AB, Dominguez-Meja A, Julius S. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation. 1994 Aug;90 (2):928–36.
  33. Liebson PR, Grandits G, Prineas R, Dianzumba S, Flack JM, Cutler JA et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993 Feb;87 (2):476–86.
  34. Cuspidi C, Sala C, Negri F, Mancia G, Morganti A. Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies. J Hum Hypertens. 2012 Jun;26 (6):343–9.
  35. Gardin JM, Wagenknecht LE, Anton-Culver H, Flack J, Gidding S, Kurosaki T et al. Relationship of cardiovascular risk factors to echocardiographic left ventricular mass in healthy young black and white adult men and women. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Circulation. 1995 Aug;92 (3):380–7.
  36. Morgan HE, Baker KM. Cardiac hypertrophy. Mechanical, neural, and endocrine dependence. Circulation. 1991 Jan;83 (1):13–25.
  37. Hannan RD, Jenkins A, Jenkins AK, Brandenburger Y. Cardiac hypertrophy: a matter of translation. Clin Exp Pharmacol Physiol. 2003 Aug;30 (8):517–27.
  38. Nadruz W. Myocardial remodeling in hypertension. J Hum Hypertens. 2015 Jan;29 (1):1–6.
  39. Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012 Apr;52 (4):857–64.
  40. Sabbah HN, Sharov VG, Goldstein S. Cell death, tissue hypoxia and the progression of heart failure. Heart Fail Rev. 2000 Jun;5 (2):131–8.
  41. Shenasa M, Shenasa H, El-Sherif N. Left ventricular hypertrophy and arrhythmogenesis. Card Electrophysiol Clin. 2015 Jun;7 (2):207–20.
  42. Saadeh AM, Jones JV. Predictors of sudden cardiac death in never previously treated patients with essential hypertension: long-term follow-up. J Hum Hypertens. 2001 Oct;15 (10):677–80.
  43. Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol. 1998 Nov;32 (5):1454–9.
  44. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham study. Ann Intern Med. 1969 Jul;71 (1):89–105.
  45. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of LV mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986 Aug;105 (2):173–8.
  46. Agabiti-Rosei E, Muiesan ML. Left ventricular hypertrophy: how to influence an important risk factor in hypertension. J Hypertens Suppl. 1998 Jan;16 (1):S53–8.
  47. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998 Jan 6–13;97 (1):48–54.
  48. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol. 2001 Dec;38 (7):1829–35.
  49. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990 May 31;322 (22):1561–6.
  50. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and risk in essential hypertension. Hypertension. 2000 Feb;35 (2):580–6.
  51. Gueyffier F, Boissel JP, Pocock S, Boutitie F, Coope J, Cutler J et al. Identification of risk factors in hypertensive patients: contribution of randomized controlled trial through an individual patient database. Circulation. 1999 Nov 2;100 (18):e88–94.
  52. Okwuosa TM, Soliman EZ, Lopez F, Williams KA, Alonso A, Ferdinand KC. Left ventricular hypertrophy and cardiovascular disease risk prediction and reclassification in blacks and whites: The Atherosclerosis Risk in Communities Study. Am Heart J. 2015 Jan;169 (1):155–61.
  53. Desai CS, Ning H, Lloyd-Jones DM. Competing cardiovascular outcomes associated with electrocardiographic left ventricular hypertrophy: the Atherosclerosis Risk in Communities Study. Heart. 2012 Feb;98 (4):330–4.
  54. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001 Mar;141 (3):334–41.
  55. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension. 2004 Apr;43 (4):731–8.
  56. Tsao CW, Gona PN, Salton CJ, Chuang ML, Levy D, Manning WJ, O’Donnell CJ. Left ventricular structure and risk of cardiovascular events: a framingham heart study cardiac magnetic resonance study. J Am Heart Assoc. 2015 Sep 15;4 (9):e002188.
  57. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, Folsom AR. The relationship of left ventricular mass and geo­metry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol. 2008 Dec 16;52 (25):2148–55.
  58. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation. 2001 Oct 2;104 (14):1615–21.
  59. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA. 2004 Nov 17;292 (19):2343–9.
  60. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004 Nov 17;292 (19):2350–6.
  61. Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens. 2008 Apr;21 (4):464–70.
  62. Scott RC, Seiwert VJ, Simon DL, McGuire J. Left ventricular hypertrophy: a study of the accuracy of current electrocardiographic criteria when compared with autopsy findings in one hundred cases. Circulation. 1955 Jan;11 (1):89–96.
  63. Pewsner D, Jüni P, Egger M, Battaglia M, Sundstrom J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007 Oct 6;335 (7622):711.
  64. Jain A, Tandri H, Dalal D, Chahal H, Soliman EZ, Prineas RJ et al. Diagnostic and prognostic utility of ecg for left ventricular hypertrophy defined by MRI in relationship to ethnicity: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J. 2010 Apr;159 (4):652–8.
  65. Devereux RB. Is ECG still useful for detection of the left ventricular hypertrophy? Circulation. 1990 Mar;81 (3):1144–6.
  66. Krittayaphong R, Nomsawadi V, Muenkaew M, Miniphan M, Yindeengam A, Udompunturak S. Accuracy of ECG criteria for the diagnosis of left ventricular hypertrophy: a comparison with magnetic resonance imaging. J Med Assoc Thai. 2013 Feb;96 (Suppl 2):S124–32.
  67. Buchner S, Debl K, Haimerl J, Djavidani B, Poschenrieder F, Feuerbach S et al. Electrocardiographic diagnosis of left ventricular hypertrophy in aortic valve disease: evaluation of ECG criteria by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2009 Jun 1;11:18.
  68. Antikainen RL, Grodzicki T, Palmer AJ, Beevers DG, Webster J, Bulpitt CJ. Left ventricular hypertrophy determined by Sokolow-Lyon criteria: a different predictor in women than in men? J Hum Hypertens. 2006 Jun;20 (6):451–9.
  69. Okin PM, Wright JT, Nieminen MS, Jern S, Taylor AL, Phillips R et al. Ethnic differences in electrocardiographic criteria for left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint. Am J Hypertens. 2002 Aug;15 (8):663–71.
  70. Okin PM, Jern S, Devereux RB, Kjeldsen SE, Dahlof B. Effect of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension. 2000 Jan;35 (1 Pt 1):13–8.
  71. Van den Hoogen JP, Mol WH, Kowsoleea A, Van Ree JW, Thien T, Van Weel C. Reproducibility of electrocardiographic criteria for left ventricular hypertrophy in hypertensive patients in general practice. Eur Heart J. 1992 Dec;13 (12):1606–10.
  72. Farb A, Devereux RB, Kligfield P. Day-to-day variability of voltage measurements used in electrocardiographic criteria for left ventricular hypertrophy. J Am Coll Cardiol. 1990 Mar 1;15 (3):618–23.
  73. McLaughlin SC, Aitchison TC, Macfarlane PW. The value of the coefficient of variation in assessing repeat variation in ECG measurements. Eur Heart J. 1998 Feb;19 (2):342–51.
  74. Angeli F, Verdecchia P, Angeli E, Poeta F, Sardone M, Bentivoglio M et al. Day-to-day variability of electrocardiographic diagnosis of left ventricular hypertrophy in hypertensive patients. Influence of electrode placement. J Cardiovasc Med (Hagerstown). 2006 Nov;7 (11):812–6.
  75. De Vries SO, Heesen WF, Beltman FW, Kroese AH, May JF, Smit AJ, Lie KI. Prediction of the left ventricular mass from the electrocardiogram in systemic hypertension. Am J Cardiol. 1996 May 1;77 (11); 974–8.
  76. Wolf HK, Burggraf GW, Cuddy E, Milliken JA, Rautaharju PM, Smith ER, Warren JW. Prediction of left ventricular mass from the electrocardiogram. J Electrocardiol. 1991 Apr;24 (2):121–7.
  77. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987 Mar;75 (3):565–72.
  78. Devereux RB, Koren MJ, de Simone G, Okin PM, Kligfield P. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J. 1993 Jul;14 (Suppl D): 8–15.
  79. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015 Jan;28 (1):1–39.e14.
  80. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977 Apr;55 (4):613–8.
  81. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986 Feb 15;57 (6):450–8.
  82. Bachenberg TC, Shub C, Hauck AJ, Edwards WD. Can anatomical left ventricular mass be estimated reliably by M-mode echocardiography? A clinicopathological study of ninety-three patients. Echocardiography. 1991 Jan;8 (1):9–15.
  83. Cuspidi C, Meani S, Negri F, Giudici V, Valerio C, Sala C et al. Indexation of left ventricular mass to body surface area and height to allometric power of 2.7: is the difference limited to obese hypertensives? J Hum Hypertens. 2009 Nov;23 (11):728–34.
  84. Abergel E, Tase M, Bohlender J, Menard J, Chatellier G. Which definition for echocardiographic left ventricular hypertrophy? Am J Cardiol. 1995 Mar 1;75 (7):498–502.
  85. Rosa EC, Moyses VA, Sesso RC, Plavnik FL, Ribeiro FF, Kohlmann NE et al. Left ventricular hypertrophy evaluation in obese hypertensive patients: effect of left ventricular mass index criteria. Arq Bras Cardiol. 2002 Apr;78 (4):341–51.
  86. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D et al. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. Hypertension. 2010 Jul;56 (1):91–8.
  87. Gosse P, Jullien V, Jarnier P, Lemetayer P, Clementy J. Echo­cardio­graphic definition of left ventricular hypertrophy in the hypertensive: which method of indexation of left ventricular mass? J Hum Hypertens. 1999 Aug;13 (8):505–9.
  88. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992 Jun;19 (7):1550–8.
  89. Sundström J, Lind L, Ärnlöv J, Zethelius B, Andren B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation. 2001 May 15;103 (19):2346–51.
  90. Lu X, Xie M, Tomberlin D, Klas B, Nadvoretskiy V, Towbin J, Ge S. How accurately, reproducibly, and efficiently can we measure left ventricular indices using M-mode, 2‑dimensional, and 3‑dimensional echocardiography in children? Am Heart J. 2008 May;155 (5):946–53.
  91. Germain P, Roul G, Kastler B, Mossard JM, Bareiss P, Sacrez A. Inter-study variability in left ventricular mass measurement. Comparison between M-mode echography and MRI. Eur Heart J. 1992 Aug;13 (8):1011–9.
  92. Bottini PB, Carr AA, Prisant LM, Flicknger FW, Allison JD, Gottdiener JS. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens. 1995 Mar;8 (3):221–8.
  93. Frohlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V et al. The heart in hypertension. N Engl J Med. 1992 Oct 1;327 (14):998–1008.
  94. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension. 2009 Nov;54 (5):1084–91.
  95. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992 Feb;5 (2):95–110.
  96. Agabiti-Rosei E, Ambrosioni E, Dal Palù C, Muiesan ML, Zanchetti A. ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J Hypertens. 1995 Nov;13 (11):1325–34.
  97. Schlaich MP, Schmieder RE. Left ventricular hypertrophy and its regression: pathophysiology and therapeutic approach: focus on treatment by antihypertenive agents. Am J Hypertens. 1998 Nov;11 (11 Pt 1):1394–404.
  98. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA. 1996 May 15;275 (19):1507–13.
  99. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G et al. Effects of once daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the Prospective Randomised Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation. 2001 Sep 11;104 (11):1248–54.
  100. Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001 Feb;19 (2):303–9.
  101. Jennings GL, Wong J. Handbook of Hypertension. Vol. 18: Assessment of Hypertensive Organ Damage. – NY: Elsevier, 1997. – P.185–223.
  102. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003 Jul;115 (1):41–6.
  103. Thürmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influ­ence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation. 1998 Nov 10;98 (19):2037–42.
  104. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001 Jun;19 (6):1167–76.
  105. Dahlof B, Zanchetti A, Diez J, Nicholls MG, Yu CM, Barrios V et al. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens. 2002 Sep;20 (9):1855–64.
  106. Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1,5 mg versus enalapril 20 mg: the LIVE study. J Hypertens. 2000 Oct;18 (10):1465–75.
  107. Schoen RE, Frishman WH, Shamoon H. Hormonal and metabolic effects of calcium channel antagonists in man. Am J Med. 1988 Mar;84 (3 Pt 1):492–504.
  108. Duprez DA, Bauwens FR, De Buyzere ML, De Backer TL, Kaufman JM, Van Hoecke J et al. Influence of arterial blood pressure and aldosterone on left ventricular hypertrophy in moderate essential hypertension. Am J Cardiol. 1993 Jan 21;71 (3):17A-20A.
  109. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol. 2000 May 15;85 (10):1199–206.
  110. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006 Jan;19 (1):13–8.
  111. Sato A, Suzuki Y, Saruta T. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res. 1999 Mar;22 (1):17–22.
  112. Taniquchi I, Kawai M, Date T, Yoshida S, Seki S, Taniguchi M et al. Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric ventricular hypertrophy. Circ J. 2006 Aug;70 (8):995–1000.
  113. Baldo MP, Forechi L, Morra EA, Zaniqueli D, Machado RC, Lunz W et al. Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness. Pharmacol Rep. 2011;63 (4):975–82.
  114. Azizi M, Perdrix L, Bobrie G, Frank M, Chatellier G, Menard J, Plouin PF. Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual rennin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. J Hypertens. 2014 Oct;32 (10):2038–44.
  115. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B et al. Effects of eplerenon, enalapril, and eplerenon / enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003 Oct 14;108 (15):1831–8.
  116. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Barfacker L et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014 Jul;64 (1):69–78.
  117. Dive V, Chang CF, Yiotakis A, Sturrock ED. Inhibition of zinc metallopeptidases in cardiovascular disease-from unity to trinity, or duality? Curr Pharm Des. 2009;15 (31):3606–21.
  118. Ferrara LA, De Simone G, Pasanisi F, Mancini M, Mancini M. Left ventricular mass reduction during salt depletion in arterial hypertension. Hypertension. 1984 Sep-Oct;6 (5):755–9.
  119. Arroll B, Beaglehole R. Does physical activity lower blood pressure: a critical review of the clinical trials. J Clin Epidemiol. 1992 May;45 (5):439–47.
  120. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med. 1986 Feb 6;314 (6):334–9.
Nechaeva G. I., Semenkin A. A., Chindareva O. I., Makhrova N. V. Left ventricular hypertrophy in arterial hypertension as an indicator of cardiovascular risk and the the goal for antihypertensive therapy. Russian Heart Journal. 2016;15 (4):235–245

To access this material please log in or register

Register Authorize
Ru En